Darcy Mootz - 23 Jul 2025 Form 4 Insider Report for Elevation Oncology, Inc. (ELEV)

Reporting relationship: Director
Issuer ticker: ELEV
Reported as of: 23 Jul 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 Jul 2025, 16:35:04 UTC
Prior SEC filing: 09 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Robert Yang, Attorney-in-Fact

Key filing fact

Darcy Mootz filed Form 4 for Elevation Oncology, Inc. (ELEV) on 24 Jul 2025.

Key facts

This page summarizes Darcy Mootz's Form 4 filing for Elevation Oncology, Inc. (ELEV).
3 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 24 Jul 2025, 16:35.

Change

Previous filing in this sequence was filed on 09 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002005916 Primary reporting owner

Mootz Darcy

Relationship: Director
Address: C/O ELEVATION ONCOLOGY, INC., 101 FEDERAL STREET, SUITE 1900, BOSTON
Signature: /s/ Robert Yang, Attorney-in-Fact
Signature date: 24 Jul 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ELEV transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -55,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 23 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 55,000
Exercise price: $2.74
Footnotes: F1, F2, F3

ELEV transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -35,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 23 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 35,000
Exercise price: $3.35
Footnotes: F1, F2, F3

ELEV transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -35,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 23 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 35,000
Exercise price: $0.3051
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Darcy Mootz is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 8, 2025, by and among Elevation Oncology, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub VI, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On July 23, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.36 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). [continues to Footnote 2]

Footnote F2

[continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3]

Footnote F3

[continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding, it was cancelled for no consideration.